Advisors Preferred’s United Therapeutics UTHR Stock Holding History

Advisors Preferred’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,780	Closed	-$4.39M	–	295
2023 Q3	$4.39M	Buy	+19,780	New	+$4.56M	1.43%	17
2020 Q4	–	Sell	-4,512	Closed	-$456K	–	207
2020 Q3	$456K	Sell	4,512 -770	-15%	-$84.5K	0.09%	52
2020 Q2	$639K	Buy	+5,282	New	+$594K	0.18%	41
2020 Q1	–	Sell	-2,859	Closed	-$252K	–	268
2019 Q4	$252K	Buy	+2,859	New	+$252K	0.07%	88
2016 Q3	–	Sell	-226	Closed	-$24K	–	274
2016 Q2	$24K	Buy	+226	New	+$25.2K	0.01%	121

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Advisors Preferred's UTHR Position: Q4 2023 in Review

Advisors Preferred sold out of United Therapeutics (UTHR) in Q4 2023, closing a stake of 19,780 shares — an estimated $4.39M sold.

Advisors Preferred first reported a position in UTHR in Q2 2016 and held it in 5 quarters. The position peaked at $4.39M in Q3 2023. 535 funds tracked by Wall St. Rank hold UTHR as of Q4 2023.

Advisors Preferred reported no remaining United Therapeutics position as of Q4 2023 after selling out during the quarter.
Advisors Preferred sold 19,780 United Therapeutics shares in Q4 2023, an estimated $4.39M.
Advisors Preferred first reported a position in United Therapeutics in Q2 2016 and held it in 5 quarters.
Advisors Preferred's United Therapeutics position peaked at $4.39M in Q3 2023.
535 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2023.

Based on Advisors Preferred's 13F filing for Q4 2023, filed 24 Jan 2024.